12/3/2020, 11:32 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Moderna

Moderna's vaccine shows potential for durable immunity

A study of Moderna Inc.'s coronavirus vaccine published in the New England Journal of Medicine revealed the candidate has the potential to provide durable immunity to the virus.

In the Phase 1 trial, led by the National Institute of Allergy and Infectious Diseases (NIAID), participants across all age groups retained high levels of neutralizing antibodies through 119 days after the first vaccination, Moderna said.

The biotechnology company also noted it expects to have 20 million doses available in the US and between 100 million and 125 million globally by year-end to be administered once its vaccine is given Food and Drug Administration (FDA) approval.

Breaking the News / NL